NAMS250117P2500
- 0.00
- 0.000.00%
NewAmsterdam Pharma Newsroom
NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank
NewAmsterdam Pharma Price Target Raised to $47.00/Share From $35.00 by Scotiabank
NewAmsterdam Pharma Analyst Ratings
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $47
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $46
Buy Rating on NewAmsterdam Pharma: Promising Phase 3 Results and Increased Price Target
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $40
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $48
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Analysts Conflicted on These Healthcare Names: NewAmsterdam Pharma Company (NAMS) and Roche Holding AG (OtherRHHVF)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
NewAmsterdam Pharma Analyst Ratings
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating